Biowest

Executive Summary

Biowest is a privately held French company founded in 1987, headquartered in Nuaille, that specializes in the production and supply of critical biological materials for life sciences research and manufacturing. With over 35 years of experience, it is a European leader in animal sera, human-origin products, cell culture media, and related reagents, distinguished by rigorous quality control and full supply chain traceability. The company holds ISO 9001:2015 and ISO 13485:2016 certifications, reflecting its commitment to quality in diagnostics and cell therapy applications. As a supplier to pharmaceutical and biotech companies, Biowest benefits from steady demand driven by the growing biopharma industry, but as a private firm, its financials and growth plans are not publicly disclosed. Given its established market position and essential role in the supply chain, Biowest is well-positioned for moderate, sustainable growth, though near-term public catalysts are limited without disclosed product pipelines or regulatory events.

Upcoming Catalysts (preview)

• Q4 2026Expansion of cell culture media production capacity75% success
• Q2 2027New partnership with a cell therapy developer for custom serum supply60% success
• Q1 2027Achievement of additional regulatory certifications (e.g., SAE, CFDA)70% success